Health News Archive - May 13, 2010
SEATTLE, May 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
DUBLIN and MYSTIC, Conn., May 13 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported selected financial results for the fiscal quarter ended March 31, 2010 and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.
WASHINGTON, May 13 /PRNewswire-USNewswire/ -- More than 600 people turned out tonight for the Lupus Foundation of America's (LFA) National Butterfly Gala, which recognized Ted Turner, Chairman, Turner Enterprises, Inc., Senator, Daniel K.
IRVINE, Calif., May 13 /PRNewswire-FirstCall/ -- The Board of Directors of Cobalis Corp. (Pink Sheets: CLSC) announced the appointment of Martin Marion as Chief Executive Officer. Mr.
MUMBAI, India, May 13, 2010 /PRNewswire/ -- Fortis Hospitals Mulund, Mumbai, performed a multiple joint replacement surgery on a 27 year old young Nigerian patient. Rebacca underwent a hip and a shoulder replacement surgery by Dr.
OKLAHOMA CITY, May 13 /PRNewswire-FirstCall/ -- Graymark Healthcare, Inc.
MINNEAPOLIS, May 13 /PRNewswire/ -- SearchAmericaÂ®, a part of Experian and a leader in financial clearing services for health care, today unveiled the newest addition to its Payment Advisor SuiteÂ® and Address Checker(SM) products, Patient Open Balance Display(SM).
BOSTON, May 13 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened offices in Chengdu and Guangzhou, China to support a growing requirement for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.
SEATTLE, May 13 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company, today announced that, based on successful preclinical studies, the Company has selected a clinical candidate for its MASP-2 antibody program and has initiated the cGMP manufacturing development process in preparation for clinical trials.